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Summary
 
The protooncogene Vav functions as a GDP/GTP exchange factor (GEF) for Rho-like small
GTPases involved in cytoskeletal reorganization and cytokine production in T cells. Gene-tar-
geted mice lacking Vav have a severe defect in positive and negative selection of T cell antigen
 
receptor transgenic thymocytes in vivo, and 
 
vav
 
2
 
/
 
2
 
 
 
thymocytes are completely resistant to
peptide-specific and anti-CD3/anti-CD28–mediated apoptosis. Vav acts upstream of mito-
chondrial pore opening and caspase activation. Biochemically, Vav regulates peptide-specific
Ca
 
2
 
1
 
 mobilization and actin polymerization. Peptide-specific cell death was blocked both by
cytochalasin D inhibition of actin polymerization and by inhibition of protein kinase C (PKC).
Activation of PKC with phorbol ester restored peptide-specific apoptosis in 
 
vav
 
2
 
/
 
2
 
 thy-
mocytes. Vav was found to bind constitutively to PKC-
 
u
 
 in thymocytes. Our results indicate
that peptide-triggered thymocyte apoptosis is mediated via Vav activation, changes in the actin
cytoskeleton, and subsequent activation of a PKC isoform.
Key words: Vav • negative selection • actin cytoskeleton • signaling transduction • protein 
kinase C
 
E
 
ngagement of the TCR initiates a cascade of molecular
events resulting in tyrosine phosphorylation of cyto-
plasmic proteins, Ca
 
2
 
1
 
 mobilization, activation of the mi-
togen-activated protein kinase (MAPK)
 
1
 
 and stress-acti-
vated protein kinase (SAPK) pathways, and reorganization
of the cytoskeleton. The protooncogene product Vav is
expressed in hematopoietic cells and is rapidly phosphory-
lated after activation of T cells by various growth factors or
by cross-linking of antigen receptors (1–3). Vav contains a
collection of structural motifs, including a pleckstrin ho-
mology (PH) domain, known to facilitate membrane local-
ization; a calponin homology (CH) domain, involved in
actin binding; one Src homology (SH)2 domain and two
SH3 domains, known to mediate protein–protein interac-
tions; and a Dbl homology (DH) domain (1, 4). In the pro-
tooncogene Dbl, the DH domain confers the capacity for
guanine nucleotide exchange for the Rho family of small
GTPases, which regulate cytoskeletal organization and SAPK/
JNK signaling (5–10). Although Vav has been implicated in
Ras and MAPK signaling (1, 11, 12), recent biochemical
and genetic studies have established a role for Vav in the
activation of Rac1 and other members of the Rho family
of small GTPases (13–15).
T cells from 
 
vav
 
2
 
/
 
2
 
 
 
mice exhibit a block in cell cycle
progression and fail to produce IL-2 in response to anti-
CD3 cross-linking (16–18). Although Vav has no apparent
role in TCR-mediated signaling pathways leading to MAPK
or SAPK activation after CD3
 
e
 
 cross-linking, Vav has been
shown to regulate TCR-mediated Ca
 
2
 
1
 
 flux and reorgani-
zation of the actin cytoskeleton. Consistent with this role,
the functional defects observed in 
 
vav
 
2
 
/
 
2
 
 T cells can be
mimicked using the actin polymerization inhibitor cyto-
chalasin D (CytD [19, 20]). In addition, Vav has been found
 
1
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-deficient Mice
 
to have a crucial role in thymocyte development and posi-
tive selection of both MHC class I– and MHC class II–
restricted TCR transgenic (Tg) thymocytes (16–18, 21).
However, it has been reported that superantigen-reactive
and alloreactive 
 
vav
 
2
 
/
 
2
 
 
 
thymocytes could still undergo neg-
ative selection (21), suggesting a differential requirement
for Vav in positive versus negative thymocyte selection.
To examine the role of Vav in the selection and activa-
tion of peptide-specific thymocytes, we introduced the H-Y
TCR (22) and the lymphocytic choriomeningitis virus
(LCMV) p33 peptide–specific P14 TCR transgenes (23)
into a 
 
vav
 
2
 
/
 
2
 
 background. We report that Vav is essential
for peptide-specific clonal deletion and TCR-triggered ap-
optosis. Vav was found to regulate peptide-specific Ca
 
2
 
1
 
mobilization and actin polymerization in thymocytes. Pep-
tide-triggered apoptosis could be blocked using the actin
polymerization inhibitor CytD and a global protein kinase
C (PKC) blocker. Among all PKC isoforms tested, only
PKC-
 
u
 
 was found to associate with Vav in thymocytes.
These results suggest that TCR-mediated changes in the
actin cytoskeleton and PKC-
 
u
 
 are crucial prerequisites for
negative selection and peptide-triggered apoptosis.
 
Materials and Methods
 
Mice.
 
Gene-targeted mice made deficient in Vav by homolo-
gous recombination (19), and H-Y and P14 TCR Tg, and P14
Tg 
 
b
 
2
 
-microglobulin (
 
b
 
2m)
 
2
 
/
 
2
 
 mice have been described previ-
ously (22, 24–27). Mice were screened for the TCR transgene
using mAbs against the Tg TCRV
 
b
 
8 chain. The 
 
vav
 
 mutation
was identified using genomic Southern blotting and PCR. Care
of animals was in accordance with institutional guidelines.
 
Reagents.
 
The PKC blockers RO-31-8220 (which blocks all
PKC isoforms) and GF109023X (which inhibits the activity of
only the Ca
 
2
 
1
 
-dependent PKC isoforms PKC-
 
a
 
, -
 
b
 
, and -
 
g
 
)
were purchased from Calbiochem Corp. (La Jolla, CA [28]). The
phosphatidylinositol 3
 
9
 
-kinase (PI3
 
9
 
K)-specific inhibitor Wort-
mannin and the fungal metabolite CytD (which blocks actin po-
lymerization) were obtained from Sigma Chemical Co. (St.
Louis, MO). Phalloidin binds specifically to polymerized filamen-
tous actin (F-actin) and was directly labeled with FITC (Sigma
Chemical Co.).
 
Induction of Apoptosis.
 
Freshly isolated thymocytes from C57BL/6
mice were cultured in RPMI 1640 medium containing 10% FCS
and 10
 
2
 
5 
 
M 
 
b
 
-mercaptoethanol in the absence or presence of
dexamethasone (Sigma Chemical Co.), anti-CD95 (clone Jo91;
PharMingen, San Diego, CA), anti-CD3
 
e
 
 (clone 145-2C11;
PharMingen), anti-CD3
 
e
 
 plus anti-CD28 (clone 37.51), or PMA
(12.5 ng/ml) plus Ca
 
2
 
1
 
 ionophore A23617 (100 ng/ml), for dif-
ferent time periods and at different concentrations as indicated in
figure legends. Optimal concentrations and activation regimes for
the induction of apoptosis were determined in pilot studies (29,
and data not shown).
 
Immunocytometry.
 
Blood samples (20 
 
m
 
l) were collected in
heparinized capillary tubes and washed once in immunofluores-
cence staining buffer (1% FCS, 0.01% NaN
 
3
 
 in PBS). Single cell
suspensions of thymocytes, spleen cells, and mesenteric lymph
node cells were prepared as described (29), resuspended in PBS,
and incubated with the appropriate mAbs for 30 min at 4
 
8
 
C. The
following mAbs were used: anti-CD4 (FITC- or PE-labeled;
PharMingen); anti-CD8 (FITC- or PE-labeled, or biotinylated;
Serotec, Inc., Raleigh, NC); anti-pan TCR-
 
a
 
/
 
b
 
 (FITC- or PE-
labeled; PharMingen); anti-TCRV
 
b
 
8.1
 
1
 
8.2 (clone KJ16, PE-labeled
or biotinylated; PharMingen); anti–H-2K
 
b
 
 (FITC-labeled or bi-
otinylated; PharMingen); anti–H-2K
 
d
 
 (FITC-labeled; PharMingen);
anti-CD5
 
 
 
(biotinylated; PharMingen); anti-CD28 (biotinylated;
PharMingen); anti-HSA (biotinylated; PharMingen); anti-CD69
(biotinylated; PharMingen); anti-CD3
 
e
 
 (FITC- or PE-labeled;
PharMingen); anti–H-Y TCR clonotype (T3.70; FITC-labeled
or biotinylated); anti-TCRV
 
b
 
8 (biotinylated; PharMingen); and
anti-P14 TCRV
 
a
 
2 (biotinylated; PharMingen). All staining
combinations were as indicated in figure legends. Biotinylated
mAbs were visualized with Streptavidin-RED670 (GIBCO BRL,
Gaithersburg, MD), and samples were analyzed using a FACScan
 
Ò
 
and Lysis II software (Becton Dickinson, Mountain View, CA).
 
Negative Selection In Vitro.
 
Thymocytes were purified from
 
vav
 
1
 
/
 
1
 
, 
 
vav
 
1
 
/
 
2
 
, and 
 
vav
 
2
 
/
 
2
 
 P14 Tg mice. P14 Tg mice express an
 
a
 
/
 
b
 
 TCR (TCRV
 
a
 
2V
 
b
 
8) specific for the strong agonist p33
peptide of LCMV. Thymocytes were cultured on EL4 cells (H-2
 
b/b
 
)
in RPMI medium containing 5% FCS and 10
 
2
 
5 
 
M 
 
b
 
-mercapto-
ethanol (2 ml final vol/well of 24-well flat-bottomed plates; Co-
star Corp., Cambridge, MA). EL4 cells (H-2
 
b/b
 
) were pulsed with
different concentrations of the deleting p33 peptide or the weak
agonist p33 peptide analogue 8.1 for 2 h before coculture with
thymocytes (26, 27, 30). Thymocytes were harvested after 10, 16,
and 22 h of incubation and stained with anti-CD4–PE, anti-
CD8–FITC, and the chromogenic dye 7-amino-actinomycin D
(7-AAD; Calbiochem Corp.). 7-AAD is a vital dye that enters
dead cells after the loss of membrane integrity and allows quanti-
tation of apoptotic cells by cytometry (FL-3 channel on a FACScan
 
Ò
 
[31]). Apoptosis was also determined by trypan blue exclusion
and by staining with propidium iodide and annexin V (R&D Sys-
tems, Inc., Minneapolis, MN). Propidium iodide and annexin V
staining of thymocytes was determined by cytofluorometry using
a FACScalibur
 
Ò
 
 (Becton Dickinson). Percent survival was calcu-
lated as [(total number of viable CD4
 
1
 
CD8
 
1
 
 thymocytes cul-
tured at different LCMV-peptide concentrations)/(total number
of viable CD4
 
1
 
CD8
 
1
 
 thymocytes from the same mouse cultured
with EL4 cells at 37
 
8
 
C in the absence of peptide)] 3 100.
Mitochondrial Permeability Transition (DCm Disruption). The mito-
chondrial transmembrane potential (DCm) results from the asym-
metric distribution of protons across the inner mitochondrial
membrane, giving rise to a chemical (pH) and electric gradient
(32, 33). The inner side of the inner mitochondrial membrane is
negatively charged. As a consequence, the cationic lipophilic flu-
orochrome 3,39-dihexyloxacarbocyanine iodide [DiOC6(3)] is
distributed on the mitochondrial matrix, correlating with DCm.
DiOC6(3) can be used to measure variations in the DCm on a per
cell basis. Cells induced to undergo apoptosis manifest an early re-
duction in the incorporation of Dcm-sensitive dyes, indicating a
disruption of Dcm. For DiOC6(3) staining, 106 thymocytes were
incubated with DiOC6(3) (final concentration 20 nM in PBS) for
20 min at 378C. DiOC6(3) staining was analyzed immediately us-
ing a FACScanÒ.
Signal Transduction. Thymocytes were isolated from nonse-
lecting b2m2/2 vav1/1, positively selecting vav1/2, and vav2/2
P14 Tg mice and cultured on a monolayer of confluent and ad-
herent MC57G fibroblasts (H-2b/b) in RPMI medium containing
5% FCS and 1025 M b-mercaptoethanol. MC57G APCs were
pulsed with different concentrations of the agonist LCMV–p33
peptide or the control AV peptide for 2 h before coculture with
thymocytes. Nonadherent thymocytes (2 3 106 P14 Tg thy-
mocytes/well) were harvested after 15, 30, 60, and 180 min of2101 Kong et al.
coculture with adherent fibroblasts and assayed for MAPK and
SAPK activation, nuclear factor kB (NF-kB) activation (IkB phos-
phorylation), and phosphotyrosine signaling (19). In brief, ty-
rosine phosphorylation was monitored in total cell lysates and im-
munoprecipitates using an antiphosphotyrosine mAb (Upstate
Biotechnology, Inc., Lake Placid, NY). Activation of SAPKs and
MAPKs was detected using phospho-SAPK– and phospho-
MAPK–specific Abs (New England Biolabs Inc., Beverly, MA).
The levels of SAPK and MAPKs (extracellular signal–regulatory
kinase [ERK]1/ERK2) were determined by immunoblotting (New
England Biolabs Inc.). Phosphorylated IkB was detected using an
mAb specific for phosphoserine (Ser32) of IkBa (New England
Biolabs Inc.). Ser32 phosphorylation of IkBa targets IkB for deg-
radation and is essential for the release of active NF-kB (34).
Immunoprecipitation. Thymocytes and peripheral lymph node T
cells were activated with anti-CD3e (1 mg/ml) for different time
periods as indicated in figure legends. Cells (107/lane) were har-
vested and lysed, and Vav was immunoprecipitated using an anti-
Vav1 Ab reactive against amino acids 576–589 (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA). Immunocomplexes were separated
by SDS-PAGE, transferred onto a membrane, and Western blotted
to detect the presence of Vav and the PKC isoforms PKC-a, -b
(-bI and -bII), -g, -d, -e, -z, -u, -i, -l, -m, and receptor for acti-
vated C-kinase 1 (RACK1). In parallel, total cell lysates (2 3 106
cells/lane) were Western blotted to ascertain the relative protein
levels of these PKC isoforms in thymocytes. All PKC isoform Abs
were purchased from Transduction Laboratories (Lexington, KY).
Peptide-specific Ca21 Mobilization. Peptide-specific Ca21 mo-
bilization ([Ca21]i) in P14 thymocytes was determined as de-
scribed (35). In brief, freshly isolated P14 Tg thymocytes (2 3
106) were loaded with 3 mM INDO-1 (Molecular Probes, Inc.,
Eugene, OR) in IMDM (pH 7.4) for 1 h at 378C. Thymocytes
were then incubated with peptide-presenting EL4 cells loaded
with either p33 or AV peptide and centrifuged (1,500 rpm, 48C)
to allow conjugate formation between thymocytes and EL4 cells.
Increases in intracellular free Ca21 were recorded in real time on
live-gated thymocyte–EL4 conjugates using a FACScaliburÒ
(Becton Dickinson).
Actin Polymerization. Thymocytes were preincubated with
PMA (12.5 ng/ml), and EL4 cells were loaded with either p33 or
AV peptide (1026 M) for 30 min on ice. Actin polymerization
was initiated by placing the cells at 378C for different time periods
as indicated in figure legends. Activation was stopped by addition
of 4% paraformaldehyde. After fixation, cells were incubated for
30 min with FITC-labeled phalloidin, which specifically binds to
polymerized F-actin. Cells were washed three times in PBS, and
phalloidin staining was analyzed using a FACScanÒ. Percentage of
peptide-specific actin polymerization (percent F-actin) was calcu-
lated as [(mean value of phalloidin fluorescence intensity of p33-
activated cells at a certain time point)/(mean value of phalloidin
fluorescence intensity of AV-activated cells at the same time
point)]  3  100.
Results
Impaired TCR-mediated Positive Selection of vav2/2 Thy-
mocytes. To analyze the role in vivo of Vav in thymocyte
selection, we introduced two rearranged TCR-a/b trans-
genes, H-Y and P14, into a vav2/2 background. The H-Y
TCR recognizes a male-specific peptide in the context of
MHC class I. Thymocytes expressing the H-Y TCR are
positively selected in female H-2b mice (22, 24, 25). The
P14 TCR is specific for a peptide epitope of the LCMV
glycoprotein p33 in the context of the MHC haplotype
H-2Db (23). In positively selecting vav1/2 mice, the develop-
ment of P141 and H-Y1 thymocytes is skewed towards the
CD81 lineage (Fig. 1, A and B). In vav2/2 mice, this bias in
favor of mature CD81 thymocytes did not occur in either
H-Y Tg or P14 Tg thymocytes (Fig. 1, A and B), and de-
velopment was in fact blocked at the immature CD41
CD81 stage of differentiation. Consistent with a block in
positive selection, TCR Tg vav2/2 thymocytes expressed
high levels of HSA and did not upregulate surface expres-
sion of the maturation and selection markers CD69, CD5
(Fig. 1 C), H-2Kb, or CD45RB (not shown). Expression of
the P14 Tg TCRVb8 and TCRVa2 chains was signifi-
cantly lower in immature CD41CD81 thymocytes of vav2/2
mice compared with CD41CD81 thymocytes from vav1/2
mice (Fig. 1 C). Similarly, expression of the H-Y Tg–
specific TCRVb8 and TCRVa3 chains detected by the
T3.70 Ab was significantly lower in H-Y Tg vav2/2 mice
(not shown). Importantly, P14 Tg vav2/2 (and H-Y Tg
vav2/2 [not shown]) thymocytes displayed a phenotype that
is similar to that of P14 Tg (and H-Y) vav1/1 b2m2/2
mice, which have a defect in positive selection of MHC
class I–restricted thymocytes (Fig. 1 C). These results show
that Vav regulates the positive selection of MHC class
I–restricted thymocytes and confirm previous data demon-
strating the crucial role of Vav in positive thymocyte selec-
tion (16–18, 21).
Impaired Negative Selection and Peptide-specific Apoptosis.
To examine the role of Vav in peptide-specific clonal dele-
tion in vivo and in vitro, we investigated the negative se-
lection of H-Y and LCMV TCR Tg thymocytes. In the
H-Y Tg system, thymocytes expressing the H-Y TCR are
positively selected in female H-2b mice but negatively se-
lected in male H-2b mice. Negative selection in male H-Y
Tg mice results in a small thymus due to deletion of
CD41CD81 thymocytes (24; Fig. 1 B). However, male
vav2/2 mice contained a large number of CD41CD81 thy-
mocytes, indicating that negative selection of H-Y Tg thy-
mocytes was severely impaired in the absence of Vav.
To further elucidate the requirement for Vav in negative
selection, an in vitro model of peptide-specific negative se-
lection was used (30). In the LCMV–p33 peptide system,
APCs are loaded with different concentrations of the
LCMV glycoprotein strong agonist peptide p33 or the
weak agonist p33 peptide analogue 8.1. Although vav1/2
P14 Tg thymocytes readily underwent apoptosis in a dose-
dependent manner in response to treatment with either the
p33 or 8.1 peptide (Fig. 2 A), vav2/2 P14 Tg thymocytes
were completely resistant to peptide-mediated apoptosis,
even at very high peptide concentrations (Fig. 2 B). Since
P14 vav2/2 thymocytes are blocked in positive T cell selec-
tion, we used b2m2/2 vav1/1 P14 TCR Tg mice (H-2b/b)
as an additional control since these mice have a block in the
positive selection of the P14 TCR due to deletion of the
MHC class I ligand (b2m2/2). The kinetics and extent of2102 Thymocyte Apoptosis in vav-deficient Mice
p33-induced apoptosis of b2m2/2  CD41CD81 P14 Tg
thymocytes were similar to those of vav1/2 P14 Tg mice,
indicating that the defect of P14 Tg vav2/2 thymocytes to
undergo peptide-specific apoptosis was not due to differ-
ences in the composition of thymocyte populations (Fig. 2
C). These results show that Vav is required for the negative
selection of peptide-specific thymocytes.
vav2/2 Thymocytes Are Resistant to CD3/CD28-mediated
Apoptosis. Immature CD41CD81 thymocytes are highly
susceptible to cell death induced by many apoptotic stimuli
(36). We evaluated the ability of vav1/2 and vav2/2 thy-
mocytes to undergo apoptosis in response to the following
stimuli: dexamethasone, PMA/Ca21 ionophore, anti-CD95
(FAS), anti-CD3e, and anti-CD3e/anti-CD28 (29, 37).
Although treatment with anti-CD3e/anti-CD28 induced
the cell death of vav1/2 CD41CD81 thymocytes, vav2/2
thymocytes were strikingly resistant to anti-CD3e/anti-
CD28–triggered apoptosis (Fig. 3). No significant differ-
ences were observed between vav2/2, vav1/2, and vav1/1
thymocytes in the extent or kinetics of cell death in re-
sponse to anti-CD95 (FAS), PMA plus Ca21 ionophore
(Fig. 3), or dexamethasone (not shown), implying that the
cellular apoptotic machinery is functional in the absence of
Vav. These data indicate that Vav is a crucial signal trans-
duction molecule involved in TCR-mediated thymocyte
apoptosis.
Vav Links TCR Signaling to Mitochondrial (Dcm) Disruption.
Disruption of the mitochondrial transmembrane potential
(Dcm) due to the opening of mitochondrial membrane pore
complex has been identified as the earliest common denomi-
nator of apoptosis (36). Alterations in mitochondria lead to
the release of “apoptosis-inducing factor” (AIF) or cytochrome
c, resulting in the activation of effector caspases such as
caspase 3 (Cpp32) (32, 38–41). To assess whether Vav links
TCR signaling to the opening of mitochondrial pores, we
determined the mitochondrial transmembrane potential
Figure 1. Impairment of positive and negative thymocyte selection in
vav2/2 mice. (A) Impaired positive selection in P14 Tg vav2/2  mice.
Non-Tg (top panels) and P14 TCR-a/b Tg (bottom panels) thymocytes
were isolated from 6-wk-old H-2b/b vav1/2 and vav2/2 mice and stained
with anti-CD4–PE and anti-CD8–FITC. Percentages of positive cells
within quadrants are indicated. Total thymocyte numbers were as follows
(mean values 6 SD; n 5 3; 6 wk of age): vav1/2 non-Tg: 11.2 6 2.5 3
107; vav2/2 non-Tg: 3.0 6 0.6 3 107; vav1/2 P14 Tg: 12.0 6 3.4 3 107;
vav2/2 P14 Tg: 7.2 6 0.6 3 107. 1 result representative of 10 experiments
is shown. (B) Impaired selection of the Tg H-Y TCR in vav2/2 mice.
Thymocytes were isolated from 5-wk-old positively selecting female (top
panels) and negatively selecting male (bottom panels) H-2b/b H-Y TCR Tg
mice and stained with anti-CD4–PE and anti-CD8–FITC. Percentages of
positive cells within quadrants are indicated. One result representative of
five experiments is shown. Total thymocyte numbers were as follows
(mean values 6 SD; n 5 3; 6 wk of age): vav1/2 female: 19.6 6 3.3 3
107; vav2/2 female: 7.5 6 0.9 3 107; vav1/2 male: 3.6 6 0.8 3 107; vav2/2
male: 13.2 6 2.6 3 107. (C) Phenotype of CD41CD81 thymocytes.
Thymocytes were isolated from P14 Tg vav2/2, P14 Tg vav1/2, and P14
Tg vav1/1 b2m2/2 mice and triple stained using anti-CD4 (PE), anti-
CD8 (FITC), and a third biotinylated Ab reactive to TCRVb8,
TCRVa2, CD28, CD69, CD5, or HSA. Histograms are shown for the
indicated surface markers (solid lines) on gated CD41CD81 thymocytes.
Broken lines, background staining using unspecific Abs. One result repre-
sentative of three experiments is shown.2103 Kong et al.
(Dcm) by cytometry using the fluorochromic dye DiOC6(3)
(33). Stimulation of P14 Tg vav1/2 thymocytes with 1026 M
p33 peptide led to measurable changes in Dcm compared
with P14 Tg vav1/2 thymocytes treated with similar con-
centrations of the nondeleting control AV peptide (com-
pare Fig. 4, A and C). However, p33 peptide–triggered
disruption of Dcm did not occur in vav2/2  thymocytes
(compare Fig. 4, B and D). Fig. 4 E shows that this effect
was dose dependent only in P14 Tg vav1/2 thymocytes.
Moreover, peptide-specific activation of the downstream
effector caspase 3 (42) did not occur in P14 Tg vav2/2 thy-
mocytes even when very high concentrations of the de-
leting p33 peptide were used (not shown). Disruption of
Dcm and caspase 3 activation occurred normally in vav2/2
thymocytes treated with dexamethasone or CD95 (not
shown).
Vav Regulates Peptide-specific Ca21 Flux and Actin Polymer-
ization. We (19) and other groups (17, 20, 21) have used
anti-CD3 cross-linking to establish that Vav links TCR/
CD3 activation to the actin cytoskeleton and Ca21 flux.
However, these experiments showed that Vav had no ap-
parent role in phosphotyrosine signaling, or in the activa-
tion of MAPK, SAPK, or NF-kB. However, the role of
Vav in peptide–MHC-mediated physiological responses
and peptide–MHC-specific signaling remained obscure. To
determine the biochemical defect in vav2/2 T cells, we an-
alyzed peptide-triggered signaling pathways in P14 TCR
Tg thymocytes from vav1/1, vav2/2, and various control
strains. Since P14 vav2/2 thymocytes are blocked in posi-
tive T cell selection, we used b2m2/2 vav1/1 P14 TCR Tg
mice (H-2b/b) as an additional control. These mice have a
block in the positive selection of the P14 TCR due to the
deletion of the MHC class I ligand (b2m2/2 [27, 43]). The
use of b2m2/2  vav1/1 P14 Tg mice ensured that thy-
mocytes expressing the Tg TCR chain had not been previ-
ously activated by the selecting MHC ligand. TCR levels
and expression of maturation markers were similar on the
thymocytes of P14 vav2/2 and P14 b2m2/2 vav1/1 mice
(Fig. 1 C).
P14 vav2/2, P14 vav1/2, and P14 b2m2/2 vav1/1 thy-
mocytes were cultured with the deleting p33 peptide or the
nondeleting control AV peptide for different time periods.
No apparent differences were observed between vav2/2,
vav1/2, and b2m2/2 vav1/1 P14 Tg thymocytes in either
the extent or kinetics of phosphotyrosine signaling, MAPK
activation, or NF-kB activation after p33 peptide–specific
activation (not shown). Intriguingly, p33 peptide–MHC-
mediated activation of either vav2/2, vav1/2, or b2m2/2
vav1/1 P14 Tg thymocytes did not lead to any detectable
SAPK/JNK activity (not shown). However, p33 peptide–
specific Ca21 mobilization was significantly decreased in
vav2/2 P14 thymocytes compared with P14 b2m2/2 vav1/1
thymocytes (compare Fig. 5, C and D) and P14 vav1/2 thy-
mocytes (not shown). Moreover, phalloidin staining exper-
iments showed that vav2/2 thymocytes exhibited a decrease
in actin polymerization and the formation of F-actin after
activation with the deleting p33 peptide (Fig. 6). Peptide–
MHC-triggered Ca21 mobilization and actin polymeriza-
tion were comparable between P14 vav1/2 and P14 b2m2/2
vav1/1 thymocytes (not shown). These results provide the
first genetic evidence that Vav links peptide-specific activa-
tion of the TCR to cytoskeletal reorganization and Ca21
mobilization.
Treatment with the actin polymerization blocker CytD
is known to mimic the functional and biochemical defects
observed in peripheral vav2/2 T cells after CD3 cross-link-
ing (20). It has also been reported that CytD addition im-
pairs peptide-induced Ca21 flux in human CD41 T cell
clones (35). Therefore, we analyzed whether CytD treat-
ment could abrogate Ca21 mobilization in freshly isolated,
wild-type P14 thymocytes. Incubation of P14 thymocytes
Figure 2. Vav regulates peptide-
specific apoptosis of P14 TCR Tg
thymocytes. P14 Tg thymocytes
were purified from vav1/2 ( A),
vav2/2  (B), and vav1/1  b2m2/2
mice and cultured on EL4 (H-2Db)
APCs pulsed with the indicated
concentrations of p33 or 8.1 pep-
tides. Cells were harvested after 22 h
of culture, and cell death was de-
termined by FACSÒ staining using
anti-CD4–PE, anti-CD8–FITC,
and a vital dye, either 7-AAD or
annexin V. Percent survival was
determined from the number of viable CD41CD81 thymocytes remain-
ing after culture in a given concentration of p33 or 8.1 peptide compared
with the number of control thymocytes remaining after culture in an
equal concentration of the control peptide AV. The AV peptide has high
affinity for H-2Db but very low affinity for the P14 TCR. Peptide con-
centrations on the x-axis indicate a range of 1026 to 10211 M. One result
representative of five experiments is shown.
Figure 3. vav2/2 thymocytes
are resistant to anti-CD3/anti-
CD28–mediated apoptosis. Cell
death was induced in vav1/2 and
vav2/2 thymocytes by treatment
with anti-CD3e, anti-CD3e plus
anti-CD28, anti-CD95 (FAS), or
PMA plus Ca21 ionophore. Per-
centage of viable CD41CD81
thymocytes remaining after treat-
ment is indicated on the y-axis.
The mean result of a triplicate
culture (6SD) representative of
three independent experiments is
shown for each activation.2104 Thymocyte Apoptosis in vav-deficient Mice
with CytD (Fig. 5 E) or chelation of extracellular Ca21 by
EGTA (Fig. 5 F) significantly decreased p33 peptide–trig-
gered Ca21 mobilization. The extent of the CytD-medi-
ated decrease in peptide-specific Ca21 flux was dependent
on the concentration of the p33 peptide (not shown).
Treatment of P14 thymocytes with CytD had no apparent
effect on the extent of tyrosine phosphorylation, NF-kB
activation, or MAPK activation (not shown). These results
Figure 4. Vav acts upstream of the mitochondrial permeability transition (Dcm disruption). (A–D) Disruption of Dcm was determined by a reduction
in the fluorescence intensity of the mitochondrial matrix chromogen DiOC6(3). Representative histograms of the changes in mitochondrial DiOC6(3) fluo-
rescence intensity are shown for thymocytes of vav1/2 (A and C) and vav2/2 (B and D) mice treated with the control AV peptide (A and B) and the de-
leting p33 peptide (C and D). EL4 APCs were loaded with 1026 M AV or p33 peptide, washed, and subsequently cultured with vav1/2 and vav2/2 thy-
mocytes for 16 h. One result representative of three independent experiments is shown. (E) Dose–response curve of Dcm disruption. Percent change in
Dcm intensity in vav1/2 and vav2/2 thymocytes treated with different concentrations of deleting p33 peptide or control AV peptide is shown. EL4 APCs
were loaded with the indicated concentration of AV or p33 peptide, washed, and subsequently cultured with vav1/2 and vav2/2 thymocytes for 10 h.
One result representative of three independent experiments is shown.
Figure 5. Vav is required for peptide-
specific Ca21 mobilization. (A–D) Ca21 flux
in freshly isolated P14 thymocytes from
b2m2/2 vav1/1 (A and C) and vav2/2 (B and
D) mice. X-axis: real time Ca21 release in
seconds; y-axis: intensity of increase of in-
tracellular Ca21 in P14 thymocytes after in-
cubation with EL4 APCs loaded with 1029
M AV (A and B) or p33 (C and D) peptide.
The Ca21 flux in b2m2/2 vav1/1 P14 thy-
mocytes was similar in intensity and kinetics
to that in vav1/1 or vav1/2 P14 thymocytes
(not shown). Similar results were obtained
in vav1/2 and vav2/2 P14 thymocytes using
higher concentrations (1028, 1027, 1026,
and 1025 M) of p33 and AV peptides (not
shown), meaning that higher peptide con-
centrations did not significantly increase the
Ca21 responses detected in b2m2/2 vav1/1,
vav1/2, or vav2/2 P14 thymocytes. One ex-
periment representative of four independent
experiments is shown. (E and F) Effect of
CytD and EGTA on Ca21 flux in freshly
isolated  b2m2/2  vav1/1 P14 thymocytes.
Ca21 flux was decreased when p33-loaded
(1029 M) EL4 APCs were pretreated 15 min
before activation with CytD (E). A similar
decrease occurred when EGTA (2.5 mM)
was added to the cells to block flux by trans-
membrane Ca21 channels (F). As a control
for loading, addition of CaCl2 into the me-
dium (F,  arrow) restored Ca21 flux in
EGTA-treated cells.2105 Kong et al.
suggest that peptide-specific actin polymerization has an
important role in the extent and duration of TCR-medi-
ated Ca21 mobilization in thymocytes.
Inhibition of Actin Polymerization Blocks Peptide-specific Thy-
mocyte Apoptosis. To further elucidate the role of Vav-
regulated changes in the actin cytoskeleton during negative
selection, we tested whether the actin polymerization in-
hibitor CytD could interfere with peptide-specific apopto-
sis of P14 TCR Tg thymocytes. Interestingly, CytD
blocked the peptide-specific cell death of vav1/1 P14 thy-
mocytes in a dose-dependent manner (Fig. 7). Similarly,
anti-CD3/anti-CD28–mediated, but not dexamethasone-
or CD95-mediated, apoptosis of vav1/1 thymocytes could
be inhibited by CytD (not shown). These data suggest that
TCR-mediated actin polymerization plays a role in pep-
tide-specific apoptosis of thymocytes.
Cooperation between Vav and PKC in Negative Selection.
The primary biochemical defects associated with signaling
in peptide-specific vav2/2 thymocytes were impaired Ca21
flux and reduced actin polymerization. Addition of Ca21
ionophore, which restores Ca21 flux in P14 vav1/2 and
Figure 6. Impaired peptide-
specific actin polymerization (F-
actin formation) in P14 vav2/2
thymocytes. Thymocytes from
P14  vav2/2 (diamonds) and vav1/2
(squares) littermates were isolated
and activated with EL4 APCs
loaded with the deleting p33
peptide (1026 M) or the control
AV peptide (1026 M) for the in-
dicated time periods. Percentage
of actin polymerization (mean
percent increase in F-actin 6
SD) is shown on the y-axis. Val-
ues were calculated as described
in Materials and Methods. The
x-axis shows the kinetics of induction in minutes after p33 stimulation.
One result representative of three independent experiments is shown.
Figure 7. Inhibition of actin
polymerization blocks peptide-
specific thymocyte apoptosis. (A)
The actin polymerization inhibi-
tor CytD blocks peptide-specific
apoptosis of P14 TCR Tg vav1/1
thymocytes induced by different
concentrations of the high-affin-
ity p33 peptide. The percentage
of viable CD41CD81 cells re-
maining after treatment is shown
on the y-axis. Peptide concen-
trations are indicated on the
x-axis and range from 1026 to
1029 M. The concentrations of
CytD used to inhibit thymocyte
apoptosis are indicated. (B) Dose–
response curve of CytD inhibi-
tion of peptide-specific apopto-
sis of P14 Tg vav1/1 thymocytes.
Percent inhibition of apoptosis is
shown on the y-axis. The con-
centration of the deleting p33 or
control AV peptide was 1029 M.
Apoptosis of CD41CD81 thy-
mocytes was detected as described in Materials and Methods. One result
representative of six experiments is shown.
Figure 8. PKC activation can restore peptide-specific apoptosis of P14
vav2/2 thymocytes. (A and B) The specific PKC activator PMA, but not
Ca21 ionophore, can rescue peptide-specific apoptosis of vav2/2 thy-
mocytes. P14 vav2/2 thymocytes (2 3 106/well) were incubated with
EL4 APCs loaded with 1029 M AV or p33 peptide plus varying concen-
trations of the Ca21 ionophore A23617 (A) or PMA (B). Higher concen-
trations of the Ca21 ionophore A23617 plus p33 peptide also failed to
trigger apoptosis (not shown). Viability of CD41CD81 thymocytes was
assessed 16 h after activation as described in Materials and Methods. It
should be noted that PMA alone induced apoptosis of CD41CD81 vav2/2
thymocytes (not shown). One result representative of three independent
experiments is shown. (C) Inhibition of p33 peptide–mediated apoptosis
of P14 TCR Tg vav1/1 thymocytes by the global PKC inhibitor RO-31-
8220. Apoptosis was induced by treatment with 1029 M p33 peptide in
the presence of the global PKC blocker RO-31-8220, GF109203X
(which only inhibits the activity of the Ca21-dependent PKC-a, -b, and
-g isoforms), or Wortmannin (a specific PI39K blocker). The percentage
of apoptotic cells is shown on the y-axis. Concentrations of pharmacolog-
ical inhibitors are shown on the x-axis (mM). Similar results were ob-
tained using different concentrations of p33 peptide or higher concentra-
tions of the inhibitors (not shown). One result representative of five
different experiments is shown. (D and E) Inhibition of p33 peptide–
mediated or PMA-mediated apoptosis of P14 TCR Tg vav1/1 thymocytes
by kinase or actin polymerization blockers. (D) Thymocytes were treated
with p33 peptide (1029M) in the absence or presence of RO-31-8220
(RO, 1 mM), the actin polymerization blocker CytD (2.5 mM), or Wort-
mannin (WT, 1 mM). (E) Thymocytes were treated with PMA (12.5 nM)
in the absence or presence of RO-31-8220, CytD, or Wortmannin at the
concentrations described for D. Unstimulated thymocytes served as con-
trols for both D and E. Results for D and E are shown as mean percent
viable CD41CD81 cells 6 SD. Percentage of apoptosis was determined
as described in Materials and Methods. One result representative of three
different experiments is shown.2106 Thymocyte Apoptosis in vav-deficient Mice
vav2/2 thymocytes (not shown), did not restore p33 pep-
tide–mediated apoptosis even when used at very high con-
centrations (100 ng/ml; Fig. 8 A). In contrast, activation of
vav2/2 P14 Tg cells with the deleting p33 peptide plus acti-
vation of PKC via the phorbol ester PMA significantly
shifted the dose–response curve of cell death in a dose-
dependent manner (Fig. 8 B). Thus, activation of PKC via
PMA, but not rescue of Ca21 flux by Ca21 ionophore, was
able to restore peptide-specific apoptosis in P14 vav2/2 thy-
mocytes, suggesting that the Vav and PKC signaling cas-
cades cooperate in the induction of TCR-mediated thy-
mocyte apoptosis. However, it should be noted that our
results do not preclude a role for Ca21 elevation in thy-
mocyte selection and clonal deletion in vivo.
Recently, it has been shown that in order for Vav to act
as a GDP/GTP exchange factor (GEF) for Rac, RhoA, or
CDC42, PI39K activity and the binding of PI39K-gener-
ated phospholipid products to the PH domain of Vav are
required (44). Therefore, we investigated whether the
specific PI39K inhibitor Wortmannin could block peptide-
specific apoptosis. As shown in Fig. 8, C and D, the inhibi-
tion of PI39K did not affect the apoptosis of P14 thy-
mocytes triggered by the deleting p33 peptide, suggesting
that the role of Vav in thymocyte apoptosis is independent
of PI39K phospholipid–dependent Vav activation. How-
ever, inhibition of PKC by the compound RO-31-8220
(which blocks all PKC isoforms) prevented peptide-specific
apoptosis in wild-type thymocytes (Fig. 8, C and D). Pep-
tide-specific apoptosis of P14 thymocytes was not blocked
by the pharmacological inhibitor GF109203X, which pre-
vents activation of Ca21-dependent PKC isoforms (Fig. 8
C). PMA-triggered apoptosis was blocked by the global
PKC blocker RO-31-8220 but not by CytD or Wortman-
nin (Fig. 8 E). These data indicate that Vav links TCR sig-
naling to activation of a Ca21-independent PKC isoform
required for the induction of peptide-specific thymocyte
apoptosis.
To further evaluate the link between Vav and PKC, we
immunoprecipitated Vav from wild-type thymocytes and
analyzed the binding of various PKC isoforms to Vav. Sur-
prisingly, Vav coimmunoprecipitated with the Ca21-inde-
pendent PKC isoform PKC-u but not with any other PKC
isoform tested (Fig. 9, left). The association between Vav
and PKC-u did not change after CD3 cross-linking, sug-
gesting that Vav/PKC-u binding is constitutive in thy-
mocytes. Constitutive Vav/PKC-u association was also ob-
served in mature peripheral T cells (not shown). Our
results do not preclude associations between Vav and low
abundance PKC isoforms.
Discussion
Our genetic and functional analyses of vav2/2 mice show
that Vav is a crucial regulator both of positive and negative
selection of CD81 thymocytes and the peptide-triggered
apoptosis of developing T cells. Vav is involved as a regula-
tor of TCR-mediated cytoskeletal reorganization and Ca21
Figure 9. Vav binds constitutively to PKC-u. Thymocytes (107 cells/
lane) were activated with anti-CD3e (1 mg/ml) for the indicated time
points. After activation, Vav was immunoprecipitated from lysates and the
complexes were Western blotted to detect the presence of different PKC
isoforms and Vav (Vav-IP; left). Right panels (Lysate) show the relative
protein levels of Vav and different PKC isoforms in total thymocyte ly-
sates (2 3 106 cells/lane). PKC-h and -k were not tested. The molecular
weights of the PKC isoforms are indicated.2107 Kong et al.
mobilization after peptide-specific activation by APCs. Our
results suggest that peptide-triggered thymocyte apoptosis
is mediated via Vav activation, changes in the actin cyto-
skeleton, and subsequent activation of a PKC isoform. This
hypothesis is based on the following findings: (a) Vav-defi-
cient thymocytes do not undergo peptide–MHC-mediated
cell death in vitro or in vivo; (b) vav2/2 thymocytes exhibit
a defect in actin polymerization, and inhibition of cytoskel-
etal changes by CytD blocks peptide–MHC-mediated and
anti-CD3/anti-CD28–mediated thymocyte apoptosis. How-
ever, inhibition of actin polymerization does not inhibit
dexamethasone-, CD95-, or PKC-mediated thymocyte ap-
optosis; (c) activation of PKC restores the susceptibility to
apoptosis of p33 peptide–triggered P14 Tg vav2/2  thy-
mocytes, and inhibition of a Ca21-independent PKC iso-
form inhibits TCR-mediated thymocyte apoptosis; and (d)
Vav associates constitutively with PKC-u but not with any
other PKC isoform. Thus, the PKC isoform PKC-u is a
good candidate for the effector kinase of negative thy-
mocyte selection.
The PKCs are a family of 11 phospholipid-dependent
serine/threonine kinases. These closely related isoenzymes
differ in their structural and biochemical properties, tissue
distribution, subcellular localization, and substrate specific-
ity (45, 46). According to primary structure and binding to
Ca21 or phorbol esters, different PKC subgroups exist:
conventional PKCs (a, bI, bII, and g) bind Ca21 and are
activated by PMA; novel PKCs (d, e, u, and h) are acti-
vated by PMA but do not bind Ca21; atypical PKCs (z, l,
i, and m) bind to diacylglycerol (DAG) but are not acti-
vated by PMA or Ca21 ionophores. Activation of PKC
molecules by lipid second messengers requires membrane
recruitment (47). T cell activation requires PKC activity.
Previously, it has been reported using PCR and Northern
blotting that PKC-a, -b, -d, -e, -z, and -u are expressed in
thymocytes (48–50). Our study shows for the first time that
all PKC isoforms are expressed in thymocytes, albeit at dif-
ferent levels. Although most PKC isoforms are expressed
ubiquitously, the isoform PKC-u is predominantly ex-
pressed in the hematopoietic system, particularly in T cells
(48–50), and has been placed upstream of IL-2 transactiva-
tion and AP1 (Fos/Jun) activity in T lymphoma cells (51,
52). Recently, it has been shown in Jurkat cells that cal-
cineurin and PKC-u cooperate in inducing IL-2 gene tran-
scription (53), a function that is reminiscent of the coordi-
nation of IL-2 expression by calcineurin and Vav/Rac1
(20, 54-57). Interestingly, the small Ras-like molecules
Rac1, CDC42, and Rho, whose activation is regulated by
Vav, may act upstream of PKC (58, 59), suggesting that Vav,
Rac1, and PKC-u may form a complex. Although Vav and
PKC-u clearly associate in thymocytes and peripheral T
cells, Rac1, CDC42, and RhoA do not coimmunoprecipi-
tate with these complexes.
Vav and Vav-regulated Rac1 and CDC42 have been
previously shown to mediate changes in the actin cytoskel-
eton and to activate SAPK/JNK (13–15, 60, 61). Similarly,
PKC-u has been placed upstream of SAPK/JNK in T cell
lines (53). However, TCR/CD28-mediated SAPK/JNK
activation appears normal in vav2/2 thymocytes and mature
T cells after anti-CD3 cross-linking (19, 20). Similarly, a
genetic mutation in the SAPK/JNK signaling pathway had
no effect on the induction of thymocyte apoptosis (29),
suggesting that Vav and perhaps PKC-u–mediated negative
selection are independent of SAPK/JNK. Importantly,
although SAPK/JNK activity is readily induced in thy-
mocytes in response to anti-CD3 and anti-CD28 Abs (62),
we failed to detect SAPK/JNK activation in thymocytes
after specific peptide–MHC-mediated stimulation. Thus,
Vav may define a novel signaling pathway that leads to nega-
tive thymocyte selection and IL-2 production in peripheral
T cells. This signaling pathway appears to be independent
of MAPK, SAPK/JNK, or NF-kB activation.
Rac1, RhoA, or CDC42 activation by Vav requires
PI39K activity in vitro (44). However, inhibition of PI39K
has no apparent effect on the peptide-triggered thymocyte
apoptosis of thymocytes, suggesting either that the role of
Vav in thymocyte apoptosis is independent of its GTP ex-
change activity for Rac and CDC42, or that Vav can func-
tion as an exchange factor even in the absence of PI39K ac-
tivity in vivo. Similarly, it has been shown that a
pharmacological PKC inhibitor, but not the PI39K inhibi-
tor Wortmannin, can block anti-CD3/anti-CD28–medi-
ated thymocyte apoptosis (63). These latter results are con-
sistent with our observation that Vav and PKC regulate
anti-CD3/anti-CD28–mediated apoptosis and imply that
PKC activation is a crucial signal in the pathway of TCR-
triggered apoptosis in developing thymocytes. Whether
PKC-u and/or other PKC isoforms are the crucial down-
stream kinases in thymocyte selections needs to be deter-
mined in genetic experiments.
Both we (19) and Holsinger et al. (20) have previously
shown that Vav regulates Ca21 mobilization and actin reor-
ganization in peripheral T cells after anti-CD3e Ab cross-
linking. The results of the present study provide the first
genetic evidence that Vav is also a crucial regulator of the
TCR-mediated Ca21 flux and actin polymerization re-
quired for thymocyte selection of peptide–MHC-stimu-
lated thymocytes. In particular, actin polymerization was
found to be crucial for the induction of apoptosis. Various
cytoskeletal proteins and regulators of cytoskeletal changes,
such as gelsolin (64–66), b-catenin (67), PAK2 (68), actin
(67, 69–76), fodrin (77), and Gas2 (76), are proteolytically
cleaved after the induction of apoptosis. Cleavage of cy-
toskeletal proteins, which occurs after caspase activation,
has an important role in the death effector phase of apopto-
sis, particularly in the regulation of membrane alterations,
morphological changes, and DNA fragmentation (68, 69).
In contrast, inhibition of actin polymerization by CytD re-
sulted in impaired TCR-mediated apoptosis. These cyto-
skeletal changes were found to act upstream of the opening
of the mitochondrial membrane pore complex and caspase
activation. However, CytD could not block apoptosis after
PKC activation (which induces rapid changes in the actin
cytoskeleton) and CytD could not protect thymocytes2108 Thymocyte Apoptosis in vav-deficient Mice
from dexamethasone- or CD95-mediated apoptosis, sug-
gesting that actin changes per se are not the principle
mechanism for conveying a cell death signal in thymocytes.
Rather, we propose that TCR-mediated and Vav-regu-
lated changes in the actin cytoskeleton lead to the recruit-
ment and/or assembly of a death effector molecule(s) that
relays the TCR signal to the apoptotic machinery.
It has been shown in the D10 T cell line that only PKC-u
translocates to the site of contact between T cells and
APCs. All other PKC isoforms (a, b1, d, h, and z) are ex-
cluded from the contact site, suggesting that PKC-u has a
specific role in T cell activation (78). Since Vav regulates
TCR clustering and PKC-u is found in these clusters, Vav-
regulated actin polymerization may be required for recruit-
ment of PKC-u to the TCR and activation of PKC at the
cell membrane. How Vav and possibly PKC-u link TCR-
mediated signals to mitochondrial apoptosis and caspase 3
activation remains to be determined. Importantly, our re-
sults show that Vav and actin polymerization also regulate
the extent and duration of peptide-specific Ca21 mobiliza-
tion, an event thought to be involved in thymocyte apop-
tosis and clonal selection (79–83).
Our data show that Vav regulates positive and negative
selection of MHC class I–restricted thymocytes. We have
previously reported that the progression of CD42CD82 T
cell precursor cells to CD41CD81 thymocytes is impaired
in vav2/2 mice on a C57BL/6 (H-2b/b) background but not
on a CD1 (H-2q/q) background (19). Thus, Vav clearly has
a role in preTCR-mediated expansion of early thymocytes,
but the absence of Vav can be partially compensated by
other signaling molecules. However, this compensatory
mechanism does not appear to be operational or sufficient
to rescue positive and negative selection of TCR Tg thy-
mocytes in vav2/2 mice. Thus, Vav either plays a different
role in TCR signaling at different stages of development
and/or different compensatory mechanisms are available to
CD42CD82 versus CD41CD81 thymocytes that make up
for the Vav mutation in the expansion from CD42CD82
to CD41CD81 cells but cannot compensate for selection
of CD41CD81 thymocytes.
Conclusion. Our data provide the first genetic evidence
for a role for Vav in peptide–MHC-triggered cytoskeletal
reorganization in vivo. These results indicate that Vav-reg-
ulated actin reorganization is a crucial prerequisite for anti-
gen receptor–mediated selection and apoptosis in peptide-
specific thymocytes. We have shown that Vav and the actin
cytoskeleton regulate the extent and duration of Ca21 mo-
bilization after peptide-specific activation, and that Vav
functions upstream of mitochondrial pore opening and
caspase activation. The defect in peptide-specific apoptosis
in vav2/2 thymocytes can be overcome by activation of
PKC, and the inhibition of PKC blocks peptide-specific
cell death in wild-type thymocytes, indicating that PKC
activation is the trigger for thymocyte apoptosis in response
to peptide. Of all PKC isoforms tested, Vav associated only
with the PKC-u isoform expressed primarily in T cells,
suggesting that PKC-u is the crucial kinase involved in thy-
mocyte selection and clonal deletion.
We thank K. Bachmaier, K. Tedford, A. Oliveira-dos-Santos, T. Sasaki, H. Nishina, A. Tafuri-Bladt, and L.
Zhang for helpful comments, and M. Saunders for scientific editing.
This work was supported by grants from the Medical Research Council of Canada (to J.M. Penninger and
A. Bernstein); from the National Cancer Institute of Canada (to A. Bernstein); and from the Deutsche For-
schungsgemeinschaft (SFB 465; to K.-D. Fischer).
Address correspondence to Josef M. Penninger, The Amgen Institute, Ontario Cancer Institute, Depart-
ments of Medical Biophysics and Immunology, University of Toronto, 620 University Ave., Toronto, On-
tario M5G 2C1, Canada. Phone: 416-204-2241; Fax: 416-204-2278; E-mail: jpenning@amgen.com
Received for publication 7 July 1998 and in revised form 10 September 1998.
References
1. Collins, T.L., M. Deckert, and A. Altman. 1997. Views on
Vav. Immunol. Today. 18:221–225.
2. Bustelo, X.R., J.A. Ledbetter, and M. Barbacid. 1992. Prod-
uct of vav proto-oncogene defines a new class of tyrosine
protein kinase substrates. Nature. 356:68–71.
3. Margolis, B., P. Hu, S. Katzav, W. Li, J.M. Oliver, A. Ull-
rich, A. Weiss, and J. Schlessinger. 1992. Tyrosine phos-
phorylation of vav proto-oncogene product containing SH2
domain and transcription factor motifs. Nature. 356:71–74.
4. Katzav, S., D. Martin-Zanca, and M. Barbacid. 1989. vav, a
novel human oncogene derived from a locus ubiquitously
expressed in hematopoietic cells. EMBO J. 8:2283–2290.
5. Teramoto, H., P. Crespo, O.A. Coso, T. Igishi, N.Z. Xu,
and J.S. Gutkind. 1996. The small GTP-binding protein rho
activates c-Jun N-terminal kinases/stress-activated protein ki-
nases in human kidney 293T cells. Evidence for a Pak-inde-
pendent signaling pathway. J. Biol.Chem. 271:25731–25734.
6. Coso, O.A., M. Chiariello, G. Kalinec, J.M. Kyriakis, J.
Woodgett, and J.S. Gutkind. 1995. Transforming G protein-
coupled receptors potently activate JNK (SAPK). Evidence
for a divergence from the tyrosine kinase signaling pathway.
J. Biol. Chem. 270:5620–5624.
7. Tapon, N., and A. Hall. 1997. Rho, Rac and Cdc42 GT-
Pases regulate the organization of the actin cytoskeleton.2109 Kong et al.
Curr. Opin. Cell Biol. 9:86–92.
8. Minden, A., A. Lin, F.X. Claret, A. Abo, and M. Karin.
1995. Selective activation of the JNK signaling cascade and
c-Jun transcriptional activity by the small GTPases Rac and
Cdc42Hs. Cell. 81:1147–1157.
9. Knaus, U.G., S. Morris, H.J. Dong, J. Chernoff, and G.M.
Bokoch. 1995. Regulation of human leukocyte p21-acti-
vated kinases through G protein–coupled receptors. Science.
269:221–223.
10. Sells, M.A., U.G. Knaus, S. Bagrodia, D.M. Ambrose, G.M.
Bokoch, and J. Chernoff. 1997. Human p21-activated kinase
(Pak1) regulates actin organization in mammalian cells. Curr.
Biol. 7:202–210.
11. Gulbins, E., K.M. Coggeshall, C. Langlet, G. Baier, N. Bonne-
foyberard, P. Burn, A. Wittinghofer, S. Katzav, and A. Alt-
man. 1994. Activation of Ras in vitro and in intact fibroblasts
by the Vav guanine nucleotide exchange protein. Mol. Cell.
Biol. 14:906–913.
12. Gulbins, E., K.M. Coggeshall, G. Baier, S. Katzav, P. Burn,
and A. Altman. 1993. Tyrosine kinase-stimulated guanine
nucleotide exchange activity of Vav in T cell activation. Sci-
ence. 260:822–825.
13. Crespo, P., K.E. Schuebel, A.A. Ostrom, J.S. Gutkind, and
X.R. Bustelo. 1997. Phosphotyrosine-dependent activation
of Rac-1 GDP/GTP exchange by the vav proto-oncogene
product. Nature. 385:169–172.
14. Crespo, P., X.R. Bustelo, D.S. Aaronson, O.A. Coso, M.
Lopez-Barahona, M. Barbacid, and J.S. Gutkind. 1996. Rac-1
dependent stimulation of the Jnk/Sapk signaling pathway by
Vav. Oncogene. 13:455–460.
15. Han, J.W., B. Das, W. Wei, L. Van Aelst, R.D. Mosteller,
R. Khosravi-Far, J.K. Westwick, C.J. Der, and D. Broek.
1997. Lck regulates Vav activation of members of the Rho
family of GTPases. Mol. Cell. Biol. 17:1346–1353.
16. Fischer, K.D., A. Zmuldzinas, S. Gardner, M. Barbacid, A.
Bernstein, and C. Guidos. 1995. Defective T-cell receptor
signalling and positive selection of Vav-deficient CD41
CD81 thymocytes. Nature. 374:474–477.
17. Tarakhovsky, A., M. Turner, S. Schaal, P.J. Mee, L.P.
Duddy, K. Rajewsky, and V.L. Tybulewicz. 1995. Defective
antigen receptor-mediated proliferation of B and T cells in
the absence of Vav. Nature. 374:467–470.
18. Zhang, R., F.W. Alt, L. Davidson, S.H. Orkin, and W. Swat.
1995. Defective signalling through the T- and B-cell antigen
receptors in lymphoid cells lacking the vav proto-oncogene.
Nature. 374:470–473.
19. Fischer, K.D., Y.Y. Kong, H. Nishina, K. Tedford, L.E.M.
Marengere, I. Kozieradzki, T. Sasaki, M. Starr, G. Chan, S.
Gardener, et al. 1998. Vav is a regulator of cytoskeletal re-
organization mediated by the T-cell receptor. Curr. Biol.
8:554–562.
20. Holsinger, L.J., I.A. Graef, W. Swat, T. Chi, D.M. Bautista,
L. Davidson, R.S. Lewis, F.W. Alt, and G.R. Crabtree.
1998. Defects in actin-cap formation in Vav-deficient mice
implicate an actin requirement for lymphocyte signal trans-
duction. Curr. Biol. 8:563–572.
21. Turner, M., P.J. Mee, A.E. Walters, M.E. Quinn, A.L. Mel-
lor, R. Zamoyska, and V.L.J. Tybulewicz. 1997. A require-
ment for the Rho-family GTP exchange factor Vav in posi-
tive and negative selection of thymocytes. Immunity. 7:451–460.
22. Teh, H.S., P. Kisielow, B. Scott, H. Kishi, Y. Uematsu, H.
Bluethmann, and H. von Boehmer. 1988. Thymic major his-
tocompatibility complex antigens and the alpha beta T-cell
receptor determine the CD4/CD8 phenotype of T cells. Na-
ture. 335:229–233.
23. Pircher, H., T.W. Mak, R. Lang, W. Ballhausen, E. Rueedi,
H. Hengartner, R.M. Zinkernagel, and K. Buerki. 1989. T
cell tolerance to Mlsa encoded antigens in T cell receptor V
beta 8.1 chain transgenic mice. EMBO J. 8:719–727.
24. von Boehmer, H., H.S. Teh, and P. Kisielow. 1989. The
thymus selects the useful, neglects the useless and destroys the
harmful. Immunol. Today. 10:57–61.
25. Kisielow, P., H.S. Teh, H. Bluethmann, and H. von Boeh-
mer. 1988. Positive selection of antigen-specific T cells in
thymus by restricting MHC molecules. Nature. 335:730–733.
26. Sebzda, E., V.A. Wallace, J. Mayer, R.S. Yeung, T.W. Mak,
and P.S. Ohashi. 1994. Positive and negative thymocyte se-
lection induced by different concentrations of a single pep-
tide. Science. 263:1615–1618.
27. Sebzda, E., T.M. Kuendig, C.T. Thomson, K. Aoki, S.Y.
Mak, J.P. Mayer, T. Zamborelli, S.G. Nathenson, and P.S.
Ohashi. 1996. Mature T cell reactivity altered by peptide ag-
onist that induces positive selection. J. Exp. Med. 183:1093–
1104.
28. Harris, W., S.E. Wilkinson, and J.S. Nixon. 1997. Recent
developments in protein kinase C inhibitors. Expert Opin.
Ther. Patents. 7:63–68.
29. Nishina, H., K.D. Fischer, L. Radvanyi, A. Shahinian, R.
Hakem, E.A. Rubie, A. Bernstein, T.W. Mak, J.R.
Woodgett, and J.M. Penninger. 1997. Stress-signalling kinase
Sek1 protects thymocytes from apoptosis mediated by CD95
and CD3. Nature. 385:350–353.
30. Pircher, H., K. Brduscha, U. Steinhoff, M. Kasai, T. Mizuo-
chi, R.M. Zinkernagel, H. Hengartner, B. Kyewski, and
K.P. Mueller. 1993. Tolerance induction by clonal deletion
of CD4181 thymocytes in vitro does not require dedicated
antigen-presenting cells. Eur. J. Immunol. 23:669–674.
31. Schmid, I., C.H. Uittenbogaart, and J.V. Giorgi. 1994. Sensi-
tive method for measuring apoptosis and cell surface pheno-
type in human thymocytes by flow cytometry. Cytometry. 15:
12–20.
32. Susin, S.A., N. Zamzami, M. Castedo, T. Hirsch, P. Mar-
chetti, A. Macho, E. Daugas, M. Geuskens, and G. Kroemer.
1996. Bcl-2 inhibits the mitochondrial release of an apopto-
genic protease. J. Exp. Med. 184:1331–1341.
33. Zamzami, N., S.A. Susin, P. Marchetti, T. Hirsch, M.-I. Go-
mez, M. Castedo, and K. Guido. 1996. Mitochondrial con-
trol of nuclear apoptosis. J. Exp. Med. 183:1533–1544.
34. Baeuerle, P.A., and D. Baltimore. 1996. NF-kappa B: ten
years after. Cell. 87:13–20.
35. Valitutti, S., M. Dessing, K. Aktories, H. Gallati, and A. Lan-
zavecchia. 1995. Sustained signaling leading to T cell activa-
tion results from prolonged T cell receptor occupancy. Role
of T cell actin cytoskeleton. J. Exp. Med. 181:577–584.
36. Penninger, J.M., and G. Kroemer. 1998. Molecular and cel-
lular mechanisms of T lymphocyte apoptosis. Adv. Immunol.
68:51–144.
37. Punt, J.A., B.A. Osborne, Y. Takahama, S.O. Sharrow, and
A. Singer. 1994. Negative selection of CD41CD81 thy-
mocytes by T cell receptor–induced apoptosis requires a co-
stimulatory signal that can be provided by CD28. J. Exp.
Med. 179:709–713.
38. Zamzami, N., P. Marchetti, M. Castedo, D. Decaudin, A.
Macho, T. Hirsch, S.A. Susin, P.X. Petit, B. Mignotte, and
G. Kroemer. 1995. Sequential reduction of mitochondrial
transmembrane potential and generation of reactive oxygen2110 Thymocyte Apoptosis in vav-deficient Mice
species in early programmed cell death. J. Exp. Med. 182:
367–377.
39. Yang, J., X. Liu, K. Bhalla, C.N. Kim, A.M. Ibrado, J. Cai,
T.I. Peng, D.P. Jones, and X. Wang. 1997. Prevention of ap-
optosis by Bcl-2: release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132.
40. Liu, X., C.N. Kim, J. Yang, R. Jemmerson, and X. Wang.
1996. Induction of apoptotic program in cell-free extracts:
requirement for dATP and cytochrome c. Cell. 86:147–157.
41. Kluck, R.M., W.-E. Bossy, D.R. Green, and D.D. New-
meyer. 1997. The release of cytochrome c from mitochon-
dria: a primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136.
42. Alam, A., M.Y. Braun, F. Hartgers, S. Lesage, L. Cohen, P.
Hugo, F. Denis, and R.P. Sekaly. 1997. Specific activation of
the cysteine protease CPP32 during the negative selection of
T cells in the thymus. J. Exp. Med. 186:1503–1512.
43. Jameson, S.C., K.A. Hogquist, and M.J. Bevan. 1995. Posi-
tive selection of thymocytes. Annu. Rev. Immunol. 13:93–126.
44. Han, J.W., K. Luby-Phelps, B. Das, X.D. Shu, Y. Xia, R.D.
Mosteller, U.M. Krishna, J.R. Falck, M.A. White, and D.
Broek. 1998. Role of substrates and products of PI 3-kinase
in regulating activation of Rac-related guanosine triphos-
phatases by Vav. Science. 279:558–560.
45. Hofmann, J. 1997. The potential for isoenzyme-selective
modulation of protein kinase C. FASEB J. 11:649–669.
46. Baron-Delage, S., and G. Cherqui. 1997. Protein kinase C
and tumorigenic potential. Bull. Cancer. 84:829–832.
47. Mochly-Rosen, D., and A.S. Gordon. 1998. Anchoring pro-
teins for protein kinase C: a means for isozyme selectivity.
FASEB J. 12:35–42.
48. Baier, G., B.-G. Baier, N. Meller, K.M. Coggeshall, L. Gi-
ampa, D. Telford, N. Isakov, and A. Altman. 1994. Expres-
sion and biochemical characterization of human protein ki-
nase C-theta. Eur. J. Biochem. 225:195–203.
49. Mischak, H., J. Goodnight, D.W. Henderson, S. Osada, S.
Ohno, and J.F. Mushinski. 1993. Unique expression pattern
of protein kinase C-theta: high mRNA levels in normal
mouse testes and in T-lymphocytic cells and neoplasms.
FEBS Lett. 326:51–55.
50. Chang, J.D., Y. Xu, M.K. Raychowdhury, and J.A. Ware.
1993. Molecular cloning and expression of a cDNA encoding
a novel isoenzyme of protein kinase C (nPKC). A new mem-
ber of the nPKC family expressed in skeletal muscle, mega-
karyoblastic cells, and platelets. J. Biol. Chem. 268:14208–
14214.
51. Szamel, M., A. Appel, R. Schwinzer, and K. Resch. 1998.
Different protein kinase C isoenzymes regulate IL-2 receptor
expression or IL-2 synthesis in human lymphocytes stimu-
lated via the TCR. J. Immunol. 160:2207–2214.
52. Baier, B.-G., F. Uberall, B. Bauer, F. Fresser, H. Wachter, H.
Grunicke, G. Utermann, A. Altman, and G. Baier. 1996.
Protein kinase C-theta isoenzyme selective stimulation of the
transcription factor complex AP-1 in T lymphocytes. Mol.
Cell. Biol. 16:1842–1850.
53. Werlen, G., E. Jacinto, Y. Xia, and M. Karin. 1998. Cal-
cineurin preferentially synergizes with PKC-theta to activate
JNK and IL-2 promoter in T lymphocytes. EMBO J. 17:
3101–3111.
54. Raab, M., A.J. da Silva, P.R. Findell, and C.E. Rudd. 1997.
Regulation of Vav-SLP-76 binding by ZAP-70 and its rele-
vance to TCR zeta/CD3 induction of interleukin-2. Immu-
nity. 6:155–164.
55. Tuosto, L., F. Michel, and O. Acuto. 1996. p95vav associates
with tyrosine-phosphorylated SLP-76 in antigen-stimulated
T cells. J. Exp. Med. 184:1161–1166.
56. Wu, J., D.G. Motto, G.A. Koretzky, and A. Weiss. 1996.
Vav and SLP-76 interact and functionally cooperate in IL-2
gene activation. Immunity. 4:593–602.
57. Jacinto, E., G. Werlen, and M. Karin. 1998. Cooperation be-
tween Syk and Rac1 leads to synergistic JNK activation in T
lymphocytes. Immunity. 8:31–41.
58. Cantrell, D. 1996. T cell antigen receptor signal transduction
pathways. Annu. Rev. Immunol. 14:259–274.
59. Arnould, T., E. Kim, L. Tsiokas, F. Jochimsen, W. Gruning,
J.D. Chang, and G. Walz. 1998. The polycystic kidney dis-
ease 1 gene product mediates protein kinase C alpha-depen-
dent and c-Jun N-terminal kinase-dependent activation of
the transcription factor AP-1. J. Biol. Chem. 273:6013–6018.
60. Khosravi, F.-R., W.-M. Chrzanowska, P.A. Solski, A. Eva,
K. Burridge, and C.J. Der. 1994. Dbl and Vav mediate trans-
formation via mitogen-activated protein kinase pathways that
are distinct from those activated by oncogenic Ras. Mol. Cell.
Biol. 14:6848–6857.
61. Olson, M.F., N.G. Pasteris, J.L. Gorski, and A. Hall. 1996.
Faciogenital dysplasia protein (FGD1) and Vav, two related
proteins required for normal embryonic development, are
upstream regulators of Rho GTPases. Curr. Biol. 6:1628–
1633.
62. Nishina, H., M. Bachmann, A.J. Oliveira-dos-Santos, I. Ko-
zieradzki, K.D. Fischer, B. Odermatt, A. Wakeham, A. Sha-
hinian, H. Takimoto, A. Bernstein, et al. 1997. Impaired
CD28-mediated interleukin 2 production and proliferation in
stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated
protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J.
Exp. Med. 186:941–953.
63. Punt, J.A., W. Havran, R. Abe, A. Sarin, and A. Singer.
1997. T cell receptor (TCR)-induced death of immature
CD41CD81 thymocytes by two distinct mechanisms differ-
ing in their requirement for CD28 costimulation: implica-
tions for negative selection in the thymus. J. Exp. Med. 186:
1911–1922.
64. Kothakota, S., T. Azuma, C. Reinhard, A. Klippel, J. Tang,
K.T. Chu, T.J. McGarry, M.W. Kirschner, K. Koths, D.J.
Kwiatkowski, and L.T. Williams. 1997. Caspase-3-generated
fragment of gelsolin: effector of morphological change in ap-
optosis. Science. 278:294–298.
65. Ohtsu, M., N. Sakai, H. Fujita, M. Kashiwagi, S. Gasa, S.
Shimizu, Y. Eguchi, Y. Tsujimoto, Y. Sakiyama, K. Koba-
yashi, and N. Kuzumaki. 1997. Inhibition of apoptosis by the
actin-regulatory protein gelsolin. EMBO J. 16:4650–4656.
66. Davoodian, K., B.W. Ritchings, R. Ramphal, and M.R.
Bubb. 1997. Gelsolin activates DNase I in vitro and in cystic
fibrosis sputum. Biochemistry. 36:9637–9641.
67. Brancolini, C., D. Lazarevic, J. Rodriguez, and C. Schneider.
1997. Dismantling cell-cell contacts during apoptosis is cou-
pled to a caspase-dependent proteolytic cleavage of beta-cate-
nin. J. Cell Biol. 139:759–771.
68. Rudel, T., and G.M. Bokoch. 1997. Membrane and mor-
phological changes in apoptotic cells regulated by caspase-
mediated activation of PAK2. Science. 276:1571–1574.
69. Villa, P.G., W.J. Henzel, M. Sensenbrenner, C.E. Hender-
son, and B. Pettmann. 1998. Calpain inhibitors, but not
caspase inhibitors, prevent actin proteolysis and DNA frag-
mentation during apoptosis. J. Cell Sci. 111:713–722.
70. Yang, F.S., X.Y. Sun, W. Beech, B. Teter, S. Wu, J. Sigel,2111 Kong et al.
H.V. Vinters, S.A. Frautschy, and G.M. Cole. 1998. Anti-
body to caspase-cleaved actin detects apoptosis in differenti-
ated neuroblastoma and plaque-associated neurons and mi-
croglia in Alzheimer’s disease. Am. J. Pathol. 152:379–389.
71. Sakahira, H., M. Enari, and S. Nagata. 1998. Cleavage of
CAD inhibitor in CAD activation and DNA degradation
during apoptosis. Nature. 391:96–99.
72. Donovan, F.M., C.J. Pike, C.W. Cotman, and D.D. Cun-
ningham. 1997. Thrombin induces apoptosis in cultured
neurons and astrocytes via a pathway requiring tyrosine ki-
nase and RhoA activities. J. Neurosci. 17:5316–5326.
73. Brown, S.B., K. Bailey, and J. Savill. 1997. Actin is cleaved
during constitutive apoptosis. Biochem. J. 323:233–237.
74. Mashima, T., M. Naito, K. Noguchi, D.K. Miller, D.W.
Nicholson, and T. Tsuruo. 1997. Actin cleavage by CPP-32/
apopain during the development of apoptosis. Oncogene. 14:
1007–1012.
75. Kayalar, C., T. Ord, M.P. Testa, L.T. Zhong, and D.E.
Bredesen. 1996. Cleavage of actin by interleukin 1 beta-con-
verting enzyme to reverse DNase I inhibition. Proc. Natl.
Acad. Sci. USA. 93:2234–2238.
76. Brancolini, C., M. Benedetti, and C. Schneider. 1995. Mi-
crofilament reorganization during apoptosis: the role of Gas2,
a possible substrate for ICE-like proteases. EMBO J. 14:
5179–5190.
77. Martin, S.J., G.A. O’Brien, W.K. Nishioka, A.J. McGahon,
A. Mahboubi, T.C. Saido, and D.R. Green. 1995. Proteoly-
sis of fodrin (non-erythroid spectrin) during apoptosis. J. Biol.
Chem. 270:6425–6428.
78. Monks, C.R., H. Kupfer, I. Tamir, A. Barlow, and A.
Kupfer. 1997. Selective modulation of protein kinase C-theta
during T-cell activation. Nature. 385:83–86.
79. Vasquez, N.J., L.P. Kane, and S.M. Hedrick. 1994. Intracel-
lular signals that mediate thymic negative selection. Immunity.
1:45–56.
80. Nakayama, T., Y. Ueda, H. Yamada, E.W. Shores, A.
Singer, and C.H. June. 1992. In vivo calcium elevations in
thymocytes with T cell receptors that are specific for self
ligands.  Science.  257:96–99.
81. Khan, A.A., M.J. Soloski, A.H. Sharp, G. Schilling, D.M. Sa-
batini, S.H. Li, C.A. Ross, and S.H. Snyder. 1996. Lympho-
cyte apoptosis: mediation by increased type 3 inositol 1,4,5-
trisphosphate receptor. Science. 273:503–507.
82. Jayaraman, T., and A.R. Marks. 1997. Cells deficient in the
inositol 1,4,5-trisphosphate receptor are resistant to apoptosis.
Mol. Cell. Biol. 17:3005–3012.
83. McConkey, D.J., P. Hartzell, P.-J.F. Amador, S. Orrenius,
and M. Jondal. 1989. Calcium-dependent killing of imma-
ture thymocytes by stimulation via the CD3/T cell receptor
complex. J. Immunol. 143:1801–1806.